查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1786624

全球融合切片检查市场

Fusion Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 277 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球融合切片检查市场规模将达到 11 亿美元

全球融合切片检查市场规模预计在2024年达到7.146亿美元，预计在分析期（2024-2030年）内将以6.7%的复合年增长率增长，到2030年将达到11亿美元。经直肠切片检查途径是本报告分析的细分市场之一，预计其复合年增长率为5.5%，到分析期结束时将达到6.409亿美元。经会阴切片检查途径细分市场在分析期间的复合年增长率预计为8.9%。

美国市场规模估计为 1.947 亿美元，中国市场预计复合年增长率为 10.3%

美国融合切片检查市场规模预计在2024年达到1.947亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到2.163亿美元，在2024-2030年的分析期间内，复合年增长率为10.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为3.4%和6.4%。在欧洲，预计德国市场的复合年增长率为4.4%。

全球融合切片检查市场－主要趋势与驱动因素摘要

融合切片检查将如何彻底改变癌症诊断？

融合切片检查因其卓越的准确性和精准定位可疑病变的能力，代表了癌症诊断，尤其是在前列腺癌检测领域的突破性进展。与仅依赖经直肠超音波(TRUS) 成像的传统切片检查方法不同，融合切片检查整合了磁振造影(MRI) 和即时超音波，从而增强了病变的可视化并提高了取样准确性。这种组合显着降低了假阴性结果和不必要重复切片检查的风险，解决了癌症诊断中长期存在的难题。由于前列腺癌发生率不断上升以及对早期准确检测的需求，融合切片检查正迅速被全球领先的医院、癌症中心和诊断实验室所采用。

医疗保健提供者日益意识到传统切片检查技术的局限性，这进一步推动了对MRI-超音波融合切片检查的需求。当PSA（前列腺特异性抗原）水平升高，但标准的TRUS引导切片检查尚无定论时，临床医生和研究人员越来越多地提倡使用MRI-超音波。此外，影像软体和人工智慧驱动的诊断工具的进步提高了病变检测的准确性，使融合切片检查成为包括肾臟、肝臟和乳房恶性肿瘤在内的各种癌症更可靠的诊断工具。随着精准医疗的不断发展，融合切片检查在早期癌症检测和改善个人化治疗方案中的作用日益凸显。

科技如何使融合切片检查更加准确和有效率？

医学影像和切片检查技术的最新创新显着提高了融合切片检查程序的效率和准确性。人工智慧影像分析增强了病变检测能力，降低了取样误差的风险，并提高了诊断信心。即时3D成像进一步优化了切片检查流程，使临床医生能够精确定位肿瘤位置并相应地调整穿刺针轨迹。此外，机器人辅助切片检查系统现已与融合切片检查平台集成，以提高准确性，最大限度地减少患者不适，并缩短手术时间。

此外，云端基础切片检查管理软体的开发简化了资料储存、分析以及病理学家和肿瘤学家之间的远端协作。这些数位平台实现了切片检查结果的无缝共用，促进了多学科癌症治疗和第二意见的咨询。此外，机器学习演算法与融合切片检查系统的整合实现了癌变组织的自动识别，减少了侵入性再次手术的需求。随着微创诊断技术的不断普及，融合切片检查有望成为切片检查诊断的标准，取代结果往往不明确或不可靠的传统活检。

哪些医学专业和医疗保健组织正在推动融合切片检查的需求？

泌尿系统仍然是推动融合切片检查需求的主要医学专科，前列腺癌诊断占其应用的大部分。领先的医院、癌症诊所和诊断影像中心正在积极投资融合切片检查系统，以改善患者预后并降低误诊率。此外，学术研究和临床试验机构正在利用融合切片检查技术探索新的生物标记并评估标靶治疗，将其应用范围扩展到标准癌症诊断之外。

除摄护腺癌外，融合切片检查在肾病学、胃肠病学和肝病学领域也日益普及，用于检测肾臟、肝臟和胰臟肿瘤。乳癌研究也受益于这项技术。当乳房X光摄影和超音波观察不确定时，融合切片检查可以更准确地进行组织取样。远端医疗和远距离诊断的普及使得融合切片检查专业知识更容易获得，即使在医疗资源匮乏、专科肿瘤影像资源匮乏的地区也是如此。随着癌症发病率的上升以及对先进诊断技术投资的不断增加，预计跨多个医学专业的融合切片检查需求将大幅增长。

推动市场成长的关键因素有哪些？

融合切片检查市场的成长受到多种因素的推动，包括影像技术的进步、癌症盛行率的上升以及对早期和精准诊断的日益重视。人工智慧辅助成像和机器人切片检查系统的广泛应用提高了手术效率，降低了取样误差，并改善了患者的预后。此外，远端医疗和云端基础诊断平台的扩展使得全球医疗机构，尤其是在肿瘤学专业知识有限的地区，更容易获得融合切片检查。

融合切片检查设备的监管核准以及新生物标誌物与诊断通讯协定的整合也推动了市场扩张。癌症诊断向微创化的转变以及个人化医疗投资的不断增加，进一步增强了对融合切片检查的需求。此外，医疗设备製造商、研究机构和医疗保健提供者之间的合作正在加速下一代切片检查系统的开发，以提高准确性、自动化程度和人工智慧主导的决策能力。随着医疗保健系统持续重视早期癌症检测，融合切片检查预计将在未来的精准肿瘤学中发挥越来越重要的作用。

部分

切片检查途径（经直肠切片检查途径、经会阴切片检查途径）；最终用途（医院最终用途、诊断中心最终用途、门诊治疗中心最终用途）

受访公司范例

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP31101

Global Fusion Biopsy Market to Reach US$1.1 Billion by 2030

The global market for Fusion Biopsy estimated at US$714.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Transrectal Biopsy Route, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$640.9 Million by the end of the analysis period. Growth in the Transperineal Biopsy Route segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$194.7 Million While China is Forecast to Grow at 10.3% CAGR

The Fusion Biopsy market in the U.S. is estimated at US$194.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$216.3 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Fusion Biopsy Market - Key Trends & Drivers Summarized

Why is Fusion Biopsy Revolutionizing Cancer Diagnostics?

Fusion biopsy has emerged as a groundbreaking advancement in cancer diagnostics, particularly in the detection of prostate cancer, due to its superior accuracy and ability to target suspicious lesions with precision. Unlike traditional biopsy methods, which rely solely on transrectal ultrasound (TRUS) imaging, fusion biopsy integrates magnetic resonance imaging (MRI) with real-time ultrasound to enhance lesion visualization and improve sampling accuracy. This combination significantly reduces the risk of false-negative results and unnecessary repeat biopsies, addressing a long-standing challenge in cancer diagnostics. Given the increasing prevalence of prostate cancer and the need for early and accurate detection, fusion biopsy is rapidly gaining adoption in leading hospitals, cancer centers, and diagnostic laboratories worldwide.

The growing awareness among healthcare providers about the limitations of conventional biopsy techniques has further fueled the demand for MRI-ultrasound fusion biopsy. Clinicians and researchers are increasingly advocating for its use in cases where PSA (prostate-specific antigen) levels are elevated but standard TRUS-guided biopsies yield inconclusive results. Additionally, advancements in imaging software and AI-driven diagnostic tools have enhanced the accuracy of lesion detection, making fusion biopsy a more reliable diagnostic tool for various forms of cancer, including kidney, liver, and breast malignancies. As precision medicine continues to evolve, the role of fusion biopsy in improving early cancer detection and personalized treatment planning is becoming more prominent.

How is Technology Enhancing the Accuracy and Efficiency of Fusion Biopsy?

Recent innovations in medical imaging and biopsy technology have significantly improved the efficiency and accuracy of fusion biopsy procedures. AI-powered image analysis has enhanced lesion detection capabilities, reducing the risk of sampling errors and improving diagnostic confidence. Real-time 3D imaging has further optimized the biopsy process by allowing clinicians to precisely map tumor locations and adjust needle trajectories accordingly. Additionally, robotic-assisted biopsy systems are being integrated with fusion biopsy platforms to increase precision, minimize patient discomfort, and reduce procedure time.

The development of cloud-based biopsy management software has also streamlined data storage, analysis, and remote collaboration among pathologists and oncologists. These digital platforms enable seamless sharing of biopsy results, facilitating multidisciplinary cancer care and second-opinion consultations. Moreover, the integration of machine learning algorithms into fusion biopsy systems is allowing for the automated identification of cancerous tissues, reducing the need for invasive repeat procedures. As the adoption of minimally invasive diagnostic techniques continues to grow, fusion biopsy is expected to become a standard of care in oncological diagnostics, replacing conventional biopsy methods that often yield inconclusive or unreliable results.

Which Medical Specialties and Healthcare Institutions Are Driving Demand for Fusion Biopsy?

Urology remains the primary medical specialty driving demand for fusion biopsy, as prostate cancer diagnosis accounts for the majority of its applications. Leading hospitals, specialty cancer clinics, and diagnostic imaging centers are actively investing in fusion biopsy systems to improve patient outcomes and reduce misdiagnosis rates. Additionally, academic research institutions and clinical trial organizations are utilizing fusion biopsy technology to study new biomarkers and evaluate targeted therapies, expanding its application beyond standard cancer diagnostics.

Beyond prostate cancer, the adoption of fusion biopsy is growing in nephrology, gastroenterology, and hepatology for the detection of kidney, liver, and pancreatic tumors. Breast cancer research is also benefiting from the technology, as fusion biopsy is enabling more precise tissue sampling in cases where mammographic and ultrasound findings are inconclusive. The expansion of telemedicine and remote diagnostics has further facilitated access to fusion biopsy expertise in underserved regions, where specialized oncological imaging was previously limited. With rising cancer incidence rates and increasing investments in advanced diagnostic technologies, the demand for fusion biopsy across multiple medical specialties is expected to surge.

What Key Factors Are Driving Market Growth?

The growth in the fusion biopsy market is driven by several factors, including advancements in imaging technology, increasing cancer incidence rates, and the growing emphasis on early and accurate diagnosis. The widespread adoption of AI-assisted imaging and robotic biopsy systems has improved procedural efficiency, reducing the likelihood of sampling errors and improving patient outcomes. Additionally, the expansion of telemedicine and cloud-based diagnostic platforms has made fusion biopsy more accessible to healthcare institutions worldwide, particularly in regions with limited oncological expertise.

Regulatory approvals for fusion biopsy devices and the integration of new biomarkers into diagnostic protocols are also fueling market expansion. The shift toward minimally invasive cancer diagnostics, coupled with rising investments in personalized medicine, has further strengthened the demand for fusion biopsy. Additionally, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating the development of next-generation biopsy systems that enhance precision, automation, and AI-driven decision-making. As healthcare systems continue to prioritize early cancer detection, fusion biopsy is expected to play an increasingly pivotal role in the future of precision oncology.

SCOPE OF STUDY:

The report analyzes the Fusion Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Biopsy Route (Transrectal Biopsy Route, Transperineal Biopsy Route); End-Use (Hospitals End-Use, Diagnostic Centers End-Use, Ambulatory Care Centers End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Artemis
  • Biobot Surgical
  • BK Medical
  • D&K Technologies
  • Eigen
  • Esaote
  • Focal Healthcare
  • GE Healthcare
  • Hitachi Medical Systems
  • innoMedicus
  • KOELIS
  • MedCom
  • Medtronic
  • Philips Healthcare
  • Profound Medical
  • Siemens Healthineers
  • SonaCare Medical
  • Toshiba Medical Systems Corporation
  • United Medical Systems
  • UroNav

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Fusion Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Prostate Cancer Drives Adoption of Fusion Biopsy for Accurate Diagnosis
    • Advancements in MRI and Ultrasound Integration Technologies Throw the Spotlight on Precision Biopsy Tools
    • Increased Focus on Minimally Invasive and Targeted Diagnostics Supports Growth of Fusion Biopsy Procedures
    • Clinical Evidence Supporting Improved Cancer Detection Rates With MRI/US Fusion Enhances Physician Confidence
    • Surge in Adoption of MRI-Visible Lesion Mapping Enables High-Precision Prostate Sampling
    • Expansion of Urology Clinics and Specialty Diagnostic Centers Fuels Market Access and Adoption
    • Growth in Medicare and Private Reimbursement Coverage Supports Procedural Volume
    • Integration of AI and Image-Guided Navigation Enhances Fusion Biopsy Accuracy and Workflow
    • Rising Demand for Outpatient Biopsy Solutions Promotes Use of Office-Based Fusion Systems
    • Development of Robotic and Semi-Automated Fusion Platforms Supports Standardization of Results
    • Global Awareness Campaigns on Early Detection of Prostate Cancer Encourage Patient Screening
    • Improved Patient Comfort and Reduced Complication Rates Drive Preference for Fusion Over TRUS-Only Biopsies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fusion Biopsy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fusion Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Transrectal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Transrectal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Transperineal Biopsy Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Transperineal Biopsy Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Care Centers End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ambulatory Care Centers End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Fusion Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Fusion Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Fusion Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Fusion Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Fusion Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Fusion Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Fusion Biopsy by Biopsy Route - Transrectal Biopsy Route and Transperineal Biopsy Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Fusion Biopsy by Biopsy Route - Percentage Breakdown of Value Sales for Transrectal Biopsy Route and Transperineal Biopsy Route for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Fusion Biopsy by End-Use - Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Fusion Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Centers End-Use and Ambulatory Care Centers End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION